title: Antivascular ultrasound therapy extends survival of mice with implanted melanomas.
abstract: The goal of this murine investigation was to evaluate the effect of an antivascular ultrasound treatment on the growth of an implanted melanoma and the consequent survival rate. After the intravenous injection of 0.2 mL ultrasound contrast agent (Definity), therapy (n = 15) was performed on 1-mL tumors for 3 min with low-intensity continuous ultrasound (3 MHz; 2.4 +/- 0.1 W cm(-2) [I(SATA)]); control mice (n = 17) received a sham treatment. Mice were euthanized once the tumor had reached 3 mL, and then survival percentage vs. time curves were plotted. The median survival time (time for tumor to reach 3 mL) for the treated group was 23 d and for the control group was 18 d; the difference was statistically significant (p <or= 0.0001). Antivascular ultrasound therapy reduced the growth rate of an implanted melanoma and increased survival time. The ultrasound therapy provides a further example of tumor vascular disruption, and its future clinical potential should be investigated.
authors.affiliation: Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Andrew K W
authors.initials: AK
authors.lastname: Wood
authors.forename: Susan M
authors.initials: SM
authors.lastname: Schultz
authors.forename: William M-F
authors.initials: WM
authors.lastname: Lee
authors.forename: Ralph M
authors.initials: RM
authors.lastname: Bunte
authors.forename: Chandra M
authors.initials: CM
authors.lastname: Sehgal
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D008545:Melanoma / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D009389:Neovascularization, Pathologic / Q000473:pathology* / Q000628:therapy*; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000379:methods*
references.citation: Eur Urol. 1993;23 Suppl 1:34-8
references.pmid: 8513832
references.citation: Clin Cancer Res. 2006 May 1;12(9):2834-40
references.pmid: 16675578
references.citation: Acta Biomed. 2008 Dec;79(3):211-6
references.pmid: 19260381
references.citation: J Clin Oncol. 2006 Apr 1;24(10):1491-8
references.pmid: 16574998
references.citation: Br J Cancer. 1982 Jan;45(1):136-9
references.pmid: 7059456
references.citation: Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6
references.pmid: 12459376
references.citation: Ultrasound Med Biol. 2006 Mar;32(3):453-61
references.pmid: 16530105
references.citation: Acad Radiol. 2009 Jan;16(1):71-8
references.pmid: 19064214
references.citation: Ultrasound Med Biol. 2007 Dec;33(12):1901-10
references.pmid: 17720299
references.citation: Eur J Cancer Clin Oncol. 1983 Feb;19(2):271-5
references.pmid: 6681772
references.citation: Acad Radiol. 2008 Sep;15(9):1133-41
references.pmid: 18692754
references.citation: Cancer Chemother Pharmacol. 1989;24(1):15-22
references.pmid: 2597279
references.citation: Ultrasound Med Biol. 2005 Oct;31(10):1403-10
references.pmid: 16223644
references.citation: Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):859-66
references.pmid: 18164835
references.citation: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7
references.pmid: 17448875
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2815-22
references.pmid: 12807934
references.citation: Br J Radiol. 2008 Oct;81 Spec No 1:S12-20
references.pmid: 18819993
references.citation: Adv Urol. 2008;:809845
references.pmid: 19132094
references.citation: Br J Cancer. 2003 Apr 22;88(8):1160-7
references.pmid: 12698178
references.citation: Lancet Oncol. 2003 Mar;4(3):141-8
references.pmid: 12623359
references.citation: Br J Cancer. 2007 Apr 23;96(8):1159-65
references.pmid: 17375046
references.citation: J Clin Pathol. 2000 May;53(5):391-4
references.pmid: 10889823
references.citation: Bioorg Med Chem. 2007 Jan 15;15(2):605-15
references.pmid: 17070061